Fountain Valley, California Clinical Trials

A listing of Fountain Valley, California clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 51 clinical trials
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B With or Without Inhibitory Antibodies to Factor VIII or IX

Primary Objective: To characterize the long-term safety and tolerability of fitusiran Secondary Objectives: To characterize the long-term efficacy of fitusiran as assessed by the frequency of: Bleeding episodes Spontaneous bleeding episodes Target joint bleeding episodes To characterize the effects of fitusiran on health-related quality of life (HRQOL) measures in participants …

hemophilia
hemarthrosis
fitusiran
haemophilia a
antihemophilic factor
Investigational Site Number 8400016
 (7.0 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +43 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

factor ix
hemophilia
antihemophilic factor
fitusiran
bethesda assay
Investigational Site Number 8400010
 (7.0 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
None

University of Southern California
 (6.6 away) Contact site
  • 0 views
  • 19 May, 2025
  • +19 other locations
A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease (RESULT)

This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or primary minimal change disease (MCD).The purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, SAR442970, or …

Investigational Site Number : 8400015
 (7.0 away) Contact site
  • 0 views
  • 20 Jun, 2025
  • +24 other locations
BCI-FES Therapy for Stroke Rehabilitation

There are over 7 million stroke survivors in the US alone, with approximately 795,000 new cases annually. Despite the best available physiotherapy, 30-60% of stroke survivors remain affected by difficulty walking, with foot weakness often being the main cause. Given that post-stroke gait impairments remain poorly addressed, new methods that …

stroke rehabilitation
spasticity
stroke
ischemic stroke
electrical stimulation
University of California, Irvine - Sue & Bill Gross Stem Cell Research Center
 (7.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
None

University of Southern California
 (6.6 away) Contact site
  • 0 views
  • 19 May, 2025
  • +12 other locations
None

University of Southern California
 (6.6 away) Contact site
  • 0 views
  • 19 May, 2025
  • +13 other locations
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

antiandrogens
combined modality therapy
docetaxel
enzalutamide
castration-resistant prostate cancer
The University of California, Irvine Medical Center
 (7.0 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +21 other locations
A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

This is a randomized, single-blind, placebo-controlled, once daily (QD) dose study of CRV431 in presumed NASH F2/F3 subjects.

fatty liver
fibroscan
vcte
fibrosis
hepatic fibrosis
Conquest Clinical Research
 (8.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +9 other locations
Development and Analysis of a Stool Bank for Cancer Patients

This study is aimed at understanding the impact of gut microbiota on efficacy of cancer therapies, in particular checkpoint inhibitors, and using the resulting information to design microbial immunotherapies. Although animal models are of use to determine the influences of gut and other microbiota on cancer treatment modalities, they are …

cancer treatment
cancer immunotherapy
pembrolizumab
immunotherapies
Compassionate Care Research Group, Inc.
 (0.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations